EcoDrugPlus

Farnesyltransferase, Caax Box, Alpha

Ensembl ID : ENSCAFG00020004303
Gene Symbol: FNTA
3 Cross references
222 Possible Orthologues:

Farnesyltransferase, Caax Box, Beta

Ensembl ID : ENSCAFG00020006858
Gene Symbol: FNTB
3 Cross references
211 Possible Orthologues:

Fatty Acid Amide Hydrolase

Ensembl ID : ENSCAFG00020015043
Gene Symbol: FAAH
3 Cross references
131 Possible Orthologues:

Fibroblast Activation Protein Alpha

Ensembl ID : ENSCAFG00020004612
Gene Symbol: FAP
3 Cross references
127 Possible Orthologues:

Fibroblast Growth Factor 2

Ensembl ID : ENSCAFG00020018322
Gene Symbol: FGF2
1 Cross references
117 Possible Orthologues:

Fibroblast Growth Factor Receptor 1

Ensembl ID : ENSCAFG00020002151
Gene Symbol: FGFR1
3 Cross references
293 Possible Orthologues:

Fibroblast Growth Factor Receptor 2

Ensembl ID : ENSCAFG00020014779
Gene Symbol: FGFR2
3 Cross references
218 Possible Orthologues:

Fibroblast Growth Factor Receptor 3

Ensembl ID : ENSCAFG00020012349
Gene Symbol: FGFR3
3 Cross references
196 Possible Orthologues:

Fibroblast Growth Factor Receptor 4

Ensembl ID : ENSCAFG00020011800
Gene Symbol: FGFR4
3 Cross references
123 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 1

Ensembl ID : ENSCAFG00020025171
Gene Symbol: FLT1
2 Cross references
199 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 3

Ensembl ID : ENSCAFG00020025240
Gene Symbol: FLT3
3 Cross references
134 Possible Orthologues:

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSCAFG00020002415
Gene Symbol: FLT4
3 Cross references
198 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).